Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis

Shi, Rui; Chen, Muzhi; Litifu, Bahaerguli

doi:10.1080/14397595.2017.1317384

Cited by 22 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, that group of patients was small, it was noticed that high survivin concentration and its positivity is independent of TNF-α treatment, what is in line with previous observations in adults with RA [7,11,18,21]. On the other hand, some researchers proved that survivin concentration is decreased in TNF-α treatment adult RA responders [24,25]. In our study biologically treated patients with JIA were previously unsuccessfully administered with conventional synthetic DMARDs for a quite long period of time (above one year).…”

Section: Resultssupporting

confidence: 83%

“…In our study biologically treated patients with JIA were previously unsuccessfully administered with conventional synthetic DMARDs for a quite long period of time (above one year). Some researchers concluded that survivin could be the marker of DMARDs non-responders [11,23,24]. However, to verify that statement in children, the group of patients with JIA treated with conventional synthetic DMARDs should be also included into the study, what is the area for future studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Concentration Of Survivin In Children With Oligo- And Poly-Articular Juvenile Idiopathic Arthritis (JIA): Diagnostic And Prognostic Value – Single Center Study.

Lipińska

Kaszkowiak

Małachowska

et al. 2021

Preprint

View full text Add to dashboard Cite

AIM: The goal of the study was to assess the diagnostic and prognostic utility of survivin in patients with Juvenile Idiopathic Arthritis (JIA).METHODS: Seventy children with JIA – 59 newly diagnosed and 11 biologically treated (46 girls and 17 boys) aged 1.5-18 years and 29 healthy children as a control group, appropriately matched in terms of sex and age, were included into the study. The disease activity was established on the basis of JADAS-27 criteria. Concentration of survivin was assessed by an ELISA test in serum and also 18 matched synovial fluid samples collected from patients with JIA.RESULTS: Children with JIA were divided according to the subtype of the JIA. In 65.7% of patients oligoarthritis was diagnosed. The largest group comprised children of low disease activity (62.9%) according to JADAS-27. The serum concentration of survivin was significantly higher in children with JIA compared to the controls (p<0.001). Concentration of survivin was higher among patients positive for anti-cyclic citrullinated peptide autoantibodies (ACPA) (p=0.001). In all synovial fluid samples the concentration of survivin was higher than in matched serum (p=0.003). Serum survivin concentration was not significantly associated with radiological damage status or active synovitis assessed by joint ultrasonography. Survivin level was not significantly associated with disease duration time or treatment with TNF-α inhibitors in DMARD’s non-responders. CONCLUSIONS: Survivin should be considered as a biomarker of joint inflammation helpful in the diagnosis of oligo- and polyatricular JIA and probably not dependent of treatment with TNF-α inhibitors.

show abstract

Section: Resultssupporting

confidence: 83%

Section: Resultsmentioning

confidence: 99%

Concentration Of Survivin In Children With Oligo- And Poly-Articular Juvenile Idiopathic Arthritis (JIA): Diagnostic And Prognostic Value – Single Center Study.

Lipińska

Kaszkowiak

Małachowska

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…IL-6 at baseline is higher in responders to both etanercept and tocilizumab [37,38]. Furthermore, Shi et al (2017) noted that high serum IL-6 and low serum survivin at baseline was associated with etanercept response with an OR of nearly 20 [37], and Diaz-Torne et al (2017) found the patients showing the greatest response to tocilizumab had a combination of high serum IL-6 and low serum soluble IL-6 receptor [38].…”

Section: Anti-citrullinated Peptide Antibodies and Rheumatoid Factormentioning

confidence: 99%

Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis

Mulhearn

Barton

2019

Preprint

View full text Add to dashboard Cite

Tumour necrosis factor-α is a key mediator of inflammation in rheumatoid arthritis its discovery led to the development of highly successful anti-TNF therapy. Subsequently, other biologic drugs targeting immune pathways, namely interleukin-6 blockade, B cell depletion, and T cell co-stimulation blockade, have been developed. Not all patients respond to a biologic drug leading to a knowledge gap between biologic therapies available and the confident prediction of response. So far, genetic studies have failed to uncover clinically informative biomarkers to predict response. Given that the targets of biologics are immune pathways, immunological study has become all the more pertinent. Furthermore, advances in single cell technology have enabled the characterisation of many leucocyte subsets. Studying the blood immunophenotype may therefore define biomarker profiles relevant to each individual patient’s disease and treatment outcome. This review summarises our current understanding of how immune biomarkers might be able to predict treatment response to biologic drugs.

show abstract

“…One could ask if the obtained results are su cient to justify the prior conclusions that survivin is the marker of DMARDs non-responders [11,23,24]. Nevertheless, the observations assessing the in uence of treatment on survivin release are con icting.…”

Section: Discussionmentioning

confidence: 95%

Concentration of survivin in children with oligo- and poly-articular juvenile idiopathic arthritis (jia): diagnostic and prognostic value – single center study.

Lipińska

Kaszkowiak

Małachowska

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: The goal of the study was to assess the diagnostic and prognostic value of survivin in Juvenile Idiopathic Arthritis (JIA).METHODS: Seventy children with JIA – 59 newly diagnosed and 11 biologically treated (46 girls and 17 boys) aged 1.5-18 years and 29 healthy children as a control group, appropriately matched in terms of sex and age, were included into the study. The disease activity was established on the basis of JADAS-27 criteria. Concentration of survivin was assessed by an ELISA test in serum and also 18 matched synovial fluid samples collected from patients with JIA.RESULTS: Children with JIA were divided according to the subtype of the JIA. In 65.7% of patients oligoarthritis was diagnosed. The largest group comprised children of low disease activity (62.9%) according to JADAS-27. The serum concentration of survivin was significantly higher in children with JIA compared to the controls (p<0.001). Concentration of survivin was higher among patients positive for anti-cyclic citrullinated peptide autoantibodies (ACPA) (p=0.001). In all synovial fluid samples the concentration of survivin was higher than in matched serum (p=0.003). Serum survivin concentration was not significantly associated with radiological damage status or active synovitis assessed by joint ultrasonography. Survivin level was not significantly associated with disease duration time or treatment with TNF-α inhibitors in DMARD’s non-responders. CONCLUSIONS: Survivin could be an independent biomarker helpful in the diagnosis of JIA. Survivin measurement should be considered as an aiding tool identifying DMARD’s non-responders.

show abstract

Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis

Abstract: Comprehensive measurement of IL-6 and survivin in serum could be served as a convincing biomarker for clinical response in ETN-treated patients with established RA.

Cited by 22 publications

References 30 publications

Concentration Of Survivin In Children With Oligo- And Poly-Articular Juvenile Idiopathic Arthritis (JIA): Diagnostic And Prognostic Value – Single Center Study.

Concentration Of Survivin In Children With Oligo- And Poly-Articular Juvenile Idiopathic Arthritis (JIA): Diagnostic And Prognostic Value – Single Center Study.

Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis

Concentration of survivin in children with oligo- and poly-articular juvenile idiopathic arthritis (jia): diagnostic and prognostic value – single center study.

Contact Info

Product

Resources

About